Published : 25 Mar 2022
Aagami has bagged an assignment to supporting Licensing/Investments needs of an Israel based revolutionary solution in IVF implantation.
The client has developed a solution with proprietary algorithms that interpret hysteroscope images to precisely identify the range of time, +/- 12 hours, when a woman undergoing IVF treatment is optimally ready to receive embryo implantation.
Current options in the industry have shockingly poor results of 30% success rate. Our client conservatively estimates they will double the success rate for IVF patients in this $25 Billion annual market.
· Sterile, single use probe incorporating a miniature camera with LEDs illumination and inflatable balloon
· Multi-use handpiece operates the mini-hysteroscope
· Clear, low hurdle regulatory (FDA, CE mark) & market entry paths
· Excellent IP portfolio (3 patent families, more in the pipeline)
· Strategic validation: JV established with world’s #1 IVF system company
· Forecast multiple-hundred million dollar annual peak revenue
· Comparable transactions suggest “unicorn” exit valuation (>$1.25B)
· Open for regional/global strategic partnerships
· Providing potential partners access to large, identifiable growing global market
Aagami are also representing the client in BIO International Convention 2022 (June 13-16, San Diego).
We are thrilled to take up this project which solves a big problem in the society, yet in a sustainable and profitable manner (win-win). If you would like to know more about this opportunity, please contact us.
Contact details:
Godwyn Francis
Vice President
M: +1-630-909-3341
Email: godwyn@aagami.com
Aagami, Inc.
2020 Calamos Court, Suite 200
Naperville IL 60563
P: +1-630-364-1837